Soley Bayraktar, Ana M. Gonzalez-Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem-Bertrandt, Henry M. Kuerer, Gabriel N. Hortobagyi, Aysegul A. Sahin and Funda Meric-Bernstam Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer Cancer 118
Article first published online: 27 SEP 2011 | DOI: 10.1002/cncr.26555
The type of neoadjuvant systemic therapy (NST) in HER2-positive breast cancer is predictive of pathologic complete response (pCR) rate independent of disease characteristics. Although TCH (docetaxel, carboplatin, and trastuzumab) is active, trastuzumab combined with an anthracycline-based NST shows a higher pCR rate and recurrence-free survival.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.